Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma Clinical Trial

Official title:
The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Status Not yet recruiting

Clinical Trial Summary

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial. Patients with unresectable perihilar and/or ductal CCA with indication for bile duct stenting and palliative systemic therapy as determined by the local multidisciplinary team (MDT), who already resolved cholestasis due to RFA + Stent will be enrolled. We hypothesize that in patients with extrahepatic cholangiocarcinoma, the use of a combination radiofrequency ablation followed by systemic treatment with chemotherapy plus durvalumab might further increase the anti-tumor activity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06440993
Study type	Interventional
Source	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Contact	Christoph Roderburg, Prof. Dr.
Phone	+49 211 8108030
Email	christoph.roderburg@med.uni-duesseldorf.de
Status	Not yet recruiting
Phase	Phase 2
Start date	July 2024
Completion date	April 2028

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05009953` - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer	Phase 2
Recruiting	`NCT06101277` - Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)	N/A
Recruiting	`NCT05448183` - An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma	Phase 2
Active, not recruiting	`NCT04333927` - Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer	Phase 2
Recruiting	`NCT04561453` - Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
Active, not recruiting	`NCT02103179` - VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)	N/A
Recruiting	`NCT05519319` - Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma	N/A
Enrolling by invitation	`NCT05233293` - Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma	N/A
Recruiting	`NCT05712356` - A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors	Phase 2